CoChat

A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer

Open access
Chiu, Wei-Yih, Shih, Shyang-Rong, Tseng, Chin-Hsiao · 2012 · Experimental Diabetes Research

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

There is a concern on the risk of thyroid cancer associated with glucagon-like peptide-1 (GLP-1) analogs including liraglutide and exenatide. In this article, we review related experimental studies, clinical trials and observational human studies currently available. In rodents, liraglutide activated the GLP-1 receptors on C-cells, causing an increased incidence of C-cell neoplasia. Animal experiments with monkeys demonstrated no increase in calcitonin release and no C-cell proliferation after long-term liraglutide administration. Longitudinal 2-year data from clinical trials do not support any significant risk for the activation or growth of C-cell cancer in humans in response to liraglutide. However, an analysis of the FDA adverse event reporting system database suggested an increased risk for thyroid cancer associated with exenatide after its marketing. Noticeably, a recent study discovered that GLP-1 receptor could also be expressed in human papillary thyroid carcinomas (PTC), but the impact of GLP-1 analogs on PTC is not known. Therefore, GLP-1 analogs might increase the risk of thyroid C-cell pathology in rodents, but its risk in humans awaits confirmation. Since GLP-1 receptor is also expressed in PTC besides C-cells, it is important to investigate the actions of GLP-1 on different subtypes of thyroid cancer in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2012/924168

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 10.1210/en.137.9.3674 · doi:10.1210/en.137.9.3674 · Paper page

Cited by

See all 63

Metadata

Authors
Chiu, W.-Y., Shih, S.-R., & Tseng, C.-H.
Affiliations
National Taiwan University (TW)
Corresponding author
Tseng, Chin-Hsiao
Venue
Experimental Diabetes Research
Publisher
Wiley
Published
2012
Volume
2012
Pages
1-7
ISSN
  • 1687-5214 (ISSN-L)
  • 1687-5303
OpenAlex
W2020816546
Cited by
63
References
35
Citations by year
2026: 6 · 2025: 5 · 2024: 6 · 2023: 9 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 8 · 2015: 4 · 2014: 3 · 2013: 10 · 2012: 1
FWCI
0.80
Type
journal article
Language
en
Open access
Locations
  • Experimental Diabetes Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
Keywords
GLP-1 receptor agonists, thyroid cancer, liraglutide, exenatide, GLP-1 receptor, drug safety, adverse drug reactions, calcitonin, type 2 diabetes
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Animals, Clinical Trials as Topic, Diabetes Mellitus, Disease Models, Animal, Gene Expression Regulation, Humans, Macaca fascicularis, Peptides, Thyroid Neoplasms, Venoms, Receptors, Glucagon, Diabetes Complications, Mice, Rats, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.